Table 1 Clinical information of the patient cohort. TTP: time interval between the start of the re-irradiation treatment and the first progression
From: FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
| Patient cohort (n = 32) | |
|---|---|
| Age (years, median, range) | 52 (30–77) |
| Sex | |
| Male | 17 (53.1%) |
| Female | 15 (46.9%) |
| GBM | |
| Unifocal | 18 (56.3%) |
| Multifocal | 14 (43.7%) |
| IDH-mutation | |
| Mutated | 10 (31.2%) |
| Wild-type | 14 (43.8%) |
| Unknown | 8 (25%) |
| MGMT-status of recurrent tumor | |
|
Methylated Not methylated Unknown |
7 (21.9%) 8 (25%) 17 (53.1%) |
| Surgery of recurrent tumor before re-irradiation | |
|
Yes No |
25 (78.1%) 7 (21.9%) |
| Time to progression (TTP) (days, median, range) | 91 (18–405) |
| Overall survival (OS) (days, median, range) | 296.5 (18–1334) |